Estrogenic activity of Derris scandens stem extracts and its major compounds using MCF-7 cell proliferation assay and estrogen-related gene expression.

Derris scandens, which contains isoflavones and prenylated derivatives, has analgesic and anti-inflammatory properties and is an ingredient in traditional Thai medicine for perimenopause and menopause. However, the estrogenic activity of D. scandens has not yet been explored. Therefore, this study aimed to examine the estrogenic activity of the stem extract of D. scandens and its isoflavone derivatives. In this study, we conducted a proliferation assay in MCF-7 cells and qRT-PCR to assess gene expression. We found that the relative cell proliferation of compounds (1 μM) was ranked in the following order as compared to 0.1 nM 17β-estradiol (100%): genistein (97.84%) > derrisisoflavone A (83.17%) > genistein-7-O-[α-rhamnopyranosyl-(1→6)-glucopyranoside] (GTG) (69.55%) > 6,8-diprenylgenistein (51.91%) > lupalbigenin (18.72%). Furthermore, co-treatment with 1 µM lupalbigenin and 0.1 nM 17β-estradiol was performed, which decreased cell proliferation to 80.38%. In vitro results suggest that lupalbigenin has an estrogen-antagonistic effect. At a dose of 1 µM, genistein had the strongest efficacy in increasing the expression of human estrogen receptor β (ERβ) by 4.0-fold compared to the control. Furthermore, GTG augmented the gene expression of human estrogen receptor α (ERα) and ERβ by 1.5- and 3.4-fold, respectively. Prenylated derivatives of genistein (derrisisoflavone A, 6,8-diprenylgenistein, and lupalbigenin) significantly suppressed the gene expression of human androgen receptor (AR). The administration of crude extract at 10 µg/mL significantly suppressed AR (0.6-fold) and transmembrane protease serine 2 (0.1-fold) expression, but did not significantly affect ERα and ERβ gene expression. This herbal medicine may be safe for estrogen-exposed breast cancer patients.